TY  - GEN
AU  - Viale,G
AU  - Regan,M M
AU  - Dell'Orto,P
AU  - Mastropasqua,M G
AU  - Maiorano,E
AU  - Rasmussen,B B
AU  - MacGrogan,G
AU  - Forbes,J F
AU  - Paridaens,R J
AU  - Colleoni,M
AU  - Láng,I
AU  - Thürlimann,B
AU  - Mouridsen,H
AU  - Mauriac,L
AU  - Gelber,R D
AU  - Price,K N
AU  - Goldhirsch,A
AU  - Gusterson,B A
AU  - Coates,A S
TI  - Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
SN  - 1569-8041
PY  - 2011///1212
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Aromatase Inhibitors
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Chemotherapy, Adjuvant
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - ErbB Receptors
KW  - biosynthesis
KW  - Female
KW  - Humans
KW  - Ki-67 Antigen
KW  - Letrozole
KW  - Middle Aged
KW  - Nitriles
KW  - Prognosis
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
KW  - Tamoxifen
KW  - Triazoles
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdq738
ER  -